These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31964314)

  • 1. Recombinant Human Thyrotropin Worsens Renal Cortical Perfusion and Renal Function in Patients After Total Thyroidectomy Due to Differentiated Thyroid Cancer.
    Saracyn M; Lubas A; Bober B; Kowalski Ł; Kapusta W; Niemczyk S; Wartofsky L; Kamiński G
    Thyroid; 2020 May; 30(5):653-660. PubMed ID: 31964314
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
    Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
    Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.
    Ippolito S; Ippolito R; Peirce C; Esposito R; Arpaia D; Santoro C; Pontieri G; Cocozza S; Galderisi M; Biondi B
    Thyroid; 2016 Nov; 26(11):1528-1534. PubMed ID: 27558484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
    Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
    Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
    Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
    Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
    Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
    Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine ablation of thyroid remnants in patients with differentiated thyroid carcinoma (DTC) following administration of rhTSH - a comparison with L-thyroxine withdrawal.
    Bałdys-Waligórska A; Gołkowski F; Krzentowska-Korek A; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2010; 61(5):474-9. PubMed ID: 21049461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy.
    Lee SJ; Lee HY; Lee WW; Kim SE
    Nucl Med Commun; 2014 Jul; 35(7):727-32. PubMed ID: 24709982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium.
    Barbaro D; Grosso M; Boni G; Lapi P; Pasquini C; Orsini P; Turco A; Meucci G; Marzola MC; Berti P; Miccoli P; Mariani G; Rubello D
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):242-9. PubMed ID: 19760415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
    Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
    Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
    Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
    Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
    Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
    Kohlfuerst S; Igerc I; Lind P
    Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyrotropin in the management of thyroid cancer.
    McDougall IR; Weigel RJ
    Curr Opin Oncol; 2001 Jan; 13(1):39-43. PubMed ID: 11148684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.